“…For these reasons, contrast-enhanced sonography would LeVeque 125 be a useful addition to a protocol for ablative therapy; however, intravenous contrast agents in the United States are currently only approved for applications related to echocardiography. 17 Considering the variables and the myriad of options available to thermal ablative technology, there is no clear preference between microwave and radiofrequency technique for clinical use. 3 Each hyperthermic energy source is unique, must be matched to the particular application at hand, and is dependent on available tools, operator discretion, skill level, and preference.…”